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Editorial
Primary Percutaneous Coronary Intervention and Risk of
Stent Thrombosis
A Look Beyond the HORIZON
Lorenz Ra¨ber, MD; Stephan Windecker, MD
Primary percutaneous coronary intervention (PCI) is thepreferred treatment for patients with ST-segment eleva-
tion myocardial infarction (STEMI) owing to improved vessel
patency, decreased infarct size, lower rates of reinfarction, and
improved survival compared with pharmacological reperfusion.
However, stent thrombosis (ST) remains a major concern among
STEMI patients with an excess 3- to 4-fold increased risk
compared with PCI in an elective setting. In the present issue of
Circulation, the Harmonizing Outcomes With Revascularization
and Stents in Acute Myocardial Infarction (HORIZONS-AMI)
trial investigators provide a detailed report of the incidence,
timing, and predictors of ST, specifically addressing the impact
of stent type and antithrombotic regimen through 2 years.1
Definite or probable ST was common (4.4%), with little more
than half of events falling into the early period (30 days), and
the remainder being observed in the late period (up to 2 years),
without apparent differences in terms of stent type and anti-
thrombotic regimen.
Primary Percutaneous Coronary Intervention
and Stent Type
A recent systematic review comparing outcomes between
drug-eluting stents (DES) and bare-metal stents (BMS) re-
ported a 56% lower risk of repeat revascularization in favor of
DES without differences in terms of death, MI, and ST.2 A
number of registry data extend the benefit of DES to more
unselected patients undergoing primary PCI in routine clini-
cal practice. Notwithstanding, there remains a nagging con-
cern about the safety of DES in STEMI patients, particularly
during long-term follow-up. What are the principal reasons
underlying this clinical equipoise?
Article see p 1745
First, very late ST has been recognized as a distinct entity
complicating the use of DES, particularly in the off-label
setting. Along this line, observational studies have reported
an increased risk of very late ST with DES compared with
BMS among STEMI patients.3,4 Second, none of the individ-
ual STEMI trials have been powered adequately to address
infrequent adverse events, such as very late ST. Third,
histopathological analysis of autopsy specimens revealed
more inflammation, fibrin deposition, and uncovered struts
among lesions treated with DES in STEMI patients compared
with those with stable lesions, suggesting a differential
arterial response to DES depending on underlying plaque
morphology.5 Fourth, late acquired stent malapposition
(LASM) was more common among DES (31%) than BMS
(8%, P0.02) 13 months after PCI in the Intravascular
Ultrasound (IVUS) substudy of HORIZONS-AMI.6 Although
it remains a matter of debate whether LASM is causally
related to very late ST, LASM in the presence of vessel
remodeling is presumably caused by extensive inflammation
elicited by DES and highly prevalent among patients pres-
enting with very late ST (75%).7 Because LASM is a dynamic
process and only appears over time, it may become clinically
apparent only during very long-term follow-up. The notion of
a differential healing response between DES and BMS among
STEMI patients is further substantiated by the Optical Co-
herence Tomography (OCT) substudy of HORIZONS-AMI,
which observed a higher rate of uncovered and malapposed
struts among DES-treated lesions at 13 months, a pattern
much like the one observed in autopsy reports.8
Despite the differential healing pattern between DES and
BMS, as evidenced in intracoronary imaging and autopsy
studies, Dangas et al in this issue of Circulation report a
similar risk of ST at all time points with the use of paclitaxel-
eluting stents and BMS during the 2-year follow-up of
HORIZONS-AMI. These seemingly contradictory observa-
tions may be due to lack of a true cause–effect relationship
between imaging findings and clinical outcome, or due to
insufficient power and lack of extended follow-up to detect
low-frequency adverse events such as ST. The first concern
can only be resolved by adequately designed studies with
serial use of intracoronary imaging to investigate the putative
role of surrogate markers. To address the second concern, and
in an attempt to look beyond the HORIZON, it is worthwhile
to analyze the time dependence of the risk of ST in available
STEMI trials comparing DES with BMS during the longest
available follow-up (Table). Although the risk of ST appears
somewhat reduced among DES-treated patients during the
first year, the frequency of very late ST is higher in most of
the trials compared with BMS at the maximal duration of
follow-up. Against this background, it is tempting to hypoth-
esize the following paradigm: DES exert a beneficial effect
among STEMI patients by reducing the risk of MI and ST
during the first year, an effect that is potentially related to
anti-inflammatory properties of the eluted therapeutic agent.
The opinions expressed in this article are not necessarily those of the
editors or of the American Heart Association.
From the Department of Cardiology and Clinical Trials Unit, Bern
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This beneficial effect may be subsequently offset (beyond 1
year) by proinflammatory properties of the polymer matrix,
resulting in hypersensitivity reactions or chronic inflamma-
tion of the treated segment.
Although all studies among STEMI patients performed
to date used early generation DES, newer generation DES
with durable and biodegradable polymer-based drug re-
lease may provide the basis for improved biocompatibility
and vascular healing. Two ongoing trials investigate newer
generation DES in the setting of STEMI: Clinical Evalu-
ation of Everolimus Eluting Coronary Stents in the Treat-
ment of Patients With ST-segment Elevation Myocardial
Infarction (EXAMINATION; NCT 00828087) compares
everolimus-eluting stents with BMS in 1504 STEMI pa-
tients, whereas Comparison of Biolimus Eluted From an
Erodable Stent Coating With Bare-Metal Stents in Acute
ST-Elevation Myocardial Infarction (COMFORTABLE
AMI; NCT 00962416) compares a stent releasing biolimus
A9 from a biodegradable polymer with BMS in 1,159
STEMI patients. If newer generation DES maintain the
early benefit compared with BMS while simultaneously
eliminating the late adverse event profile, an important
progress in the treatment of STEMI patients could appear
on the HORIZON.
Primary Percutaneous Coronary Intervention
and Antithrombotic Regimen
ST-segment elevation myocardial infarction is mostly caused
by rupture of inflamed plaques with exposure of the throm-
bogenic lipid-rich core, resulting in platelet aggregation and
tissue factor-mediated activation of the coagulation cascade
with thrombin generation. Unlike unfractionated (UFH) and
low–molecular-weight heparin, direct thrombin inhibitors
block not only soluble, but also clot-bound, thrombin, which
is the theoretical underpinning of the more specific, and
potentially more effective, profile of these agents. In this
context, HORIZONS-AMI compared an antithrombotic strat-
egy of bivalirudin monotherapy with the combined use of
UFH plus a glycoprotein IIb/IIIa antagonist among STEMI
patients. Although the 2-year cumulative incidence of ST was
similar for both antithrombotic regimens, acute ST was more
common among patients treated with bivalirudin, and bivali-
rudin use emerged as a strong independent predictor of acute
ST. A few limitations are notable, including the open-label
design, the administration of UFH before randomization in
two thirds of patients, and the variable clopidogrel loading
dose. Moreover, it is arguable whether late and very late ST
are in any way related to the periprocedural antithrombotic
regimen. Of note, the 1.1% incremental risk of acute ST with
bivalirudin monotherapy must be weighed against its benefits
and overall clinical outcome. Thus, bivalirudin monotherapy
compared with UFH plus glycoprotein IIb/IIIa antagonists
was associated with a significant decrease in major bleeding
and, more importantly, a significantly lower mortality at 30
days and 1 year, presumably because of fewer deaths from
bleeding causes, rendering the excess mortality in acute ST
inconsequential.
Two observations emerge from the present study, which
may provide guidance in the search for the most effective
periprocedural antithrombotic regimen. First, prerandomiza-
tion use of UFH was a strong predictor of freedom from acute
ST, and lowered its risk by 73%. This finding may point to
the importance of more potent and prolonged thrombin
inhibition. Because of its short half-life, the antithrombotic
effects of bivalirudin are quickly reversible, but may uncover
residual thrombin activity, which may play a role in the
genesis of recurrent ischemic events. The prolonged admin-
istration (median 7 days) of low–molecular-weight heparin
was more effective than a short duration of UFH (median 2
days) in the prevention of death and MI among STEMI
patients included in the Enoxaparin and Thrombolysis Rep-
erfusion for Acute Myocardial Infarction Treatment—
Thrombolysis in Myocardial Infarction 25 (ExTRACT-TIMI
25) trial.9 The difference only emerged at the time of
discontinuation of UFH, suggesting that a prolonged anti-
thrombin regimen is beneficial. One therapeutic option to
mitigate the increased risk of acute ST could therefore be a
prolonged infusion of bivalirudin after PCI in STEMI pa-
tients, even though this strategy may abrogate the advantage
of a lower bleeding risk.
Second, use of high-dose (600 mg) clopidogrel loading was
a strong predictor of freedom from subacute ST. The higher
loading dose affords more rapid and greater inhibition of
platelet aggregation than the standard (300 mg) regimen, and
reduced the risk of subacute ST by 48% in the present study.
Similar findings have been observed in the Clopidogrel
Optimal Loading Dose Usage to Reduce Recurrent EveNTs/
Optimal Antiplatelet Strategy for Interventions (CURRENT
OASIS 7) trial,10 with a 46% lower risk of definite ST after
a high- rather than a standard-dose clopidogrel regimen
among patients with acute coronary syndromes undergoing
PCI. Of note, the protective effect of high-dose clopidogrel to
prevent ST in the present study was restricted to the subacute
phase and not apparent during the acute phase, highlighting
the delayed onset of action of this type of oral P2Y12
inhibitor. This shortcoming may be overcome by newer
antiplatelet agents with more rapid, intense, and consistent
inhibition of platelet aggregation. Compared with high load-
ing dose clopidogrel, prasugrel as well as ticagrelor achieve a
greater degree of platelet inhibition as soon as 30 minutes,
which is maintained throughout 24 hours. Moreover, prasu-
grel and ticagrelor lowered the risk of definite ST compared
with clopidogrel by 58% and 33%, respectively, in large-
scale clinical trials of acute coronary syndrome patients.11,12
Accordingly, the combination of prasugrel or ticagrelor with
bivalirudin may become an attractive therapeutic option,
particularly among STEMI patients, as none of the antiplate-
let drugs were associated with an increased risk of bleeding in
this patient population.
As is true of any great study, the results of HORIZONS-AMI
not only contribute to the current standard of care, but also
stimulate numerous important questions and hypotheses. Our
blurred look of what appears on the HORIZON will be
sharpened by future investigations addressing some of the
hypotheses outlined above.
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